Michael C. Heinrich, MD

Michael C. Heinrich is a professor of medicine at Oregon Health and Science University. He specializes in chronic myeloid leukemia, gastrointestinal stromal tumors, and leukemia.

Articles by Michael C. Heinrich, MD

Velzatinib Aims For Future Direct Comparison With Imatinib in GIST

ByMichael C. Heinrich, MD

June 3rd 2026

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors.

Leveraging ctDNA Subgroups and Clearance Metrics For Velzatinib in GIST

ByMichael C. Heinrich, MD

June 2nd 2026

Michael C. Heinrich, MD, discusses promising KIT mutation analyses from the phase 1b StrateGIST study in gastrointestinal stromal tumors.

Michael C. Heinrich, MD

Articles by Michael C. Heinrich, MD

Velzatinib Aims For Future Direct Comparison With Imatinib in GIST

Leveraging ctDNA Subgroups and Clearance Metrics For Velzatinib in GIST

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma

De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival

Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up

Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC

CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC